COMPARISON
Lanreotide vs Teriparatide
6 attributes held for at least one of the two. 6 differ. Each value carries the register it came from and the date that register was read.
Answer
Lanreotide is authorised or registered in 9 and Teriparatide in 10 of the 10 registers read. Lanreotide: highest phase Phase 4 (after approval). Teriparatide: highest phase Phase 4 (after approval). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Lanreotide | Teriparatide | |
|---|---|---|
| Registered trials differs | 125 clinicaltrials.gov · 2026-10-03 | 185 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Lanreotide Acetate openfda · 2026-10-03T17:23:44.062Z | FDA-approved: teriparatide openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Nothing on record ema read 2026-08-31 | Authorised ema · 2026-10-03 |
| EU authorised on differs | Not checked no record of "authorisedOn" for lanreotide | 2003-06-10 ema · 2026-10-03 |
| EU withdrawn on differs | Not checked no record of "withdrawnOn" for lanreotide | 2020-11-24 ema · 2026-10-03 |
| ATC code differs | Not checked no record of "atcCode" for lanreotide | H05AA02 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Lanreotide | placebo | Teriparatide | placebo |
|---|---|---|---|---|
| Nausea | 11.0% | 12.0% | 6.3% | 3.8% |
| Headache | 10.7% | 9.4% | 7.6% | 6.5% |
| Arthralgia | 8.0% | 8.2% | 9.1% | 9.2% |
| Back pain | 8.0% | 10.3% | 9.5% | 10.2% |
| Diarrhoea | 19.5% | 23.6% | - | - |
| Abdominal pain | 16.8% | 15.9% | - | - |
| Fatigue | 12.2% | 14.6% | - | - |
| Vomiting | 10.8% | 7.8% | - | - |
| Hypertension | 8.8% | 5.6% | - | - |
| Decreased appetite | 8.0% | 8.6% | - | - |
| Nasopharyngitis | - | - | 14.1% | 13.4% |
| Hypercalciuria | - | - | 11.3% | 6.7% |
| Upper respiratory tract infection | - | - | 7.0% | 5.6% |
| Dizziness | - | - | 6.8% | 5.2% |
| Pain in extremity | - | - | 6.0% | 5.2% |
| Constipation | - | - | 5.3% | 4.5% |
Trial register Lanreotide: 5 placebo-controlled trials; Teriparatide: 11. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Lanreotide side effects · Teriparatide side effects
LEGAL STATUS
Approval in each country read
| Country | Lanreotide | Teriparatide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Not on the register | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.